GT Biopharma Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Hello, everyone, and thank you for joining the H.C. Wainwright 24th Annual Global Investment Hybrid Conference. My name is Jason Shieh, and I'm a H.C. Wainwright healthcare research associate. I'd like to welcome our next speaker, Michael Breen, Interim CEO, Executive Chairman, Board of Directors; and Gavin Choy, Chief Clinical Development Officer of GT Biopharma, a clinical stage immuno-oncology company, focused on developing innovative therapeutic based on proprietary natural killer cell engager known as TriKE. And thank you, gentlemen.
Thank you, Jason. Good morning, everyone, and thank you for taking the time to join us this morning and listen to our presentation. Much appreciated. And if I can just take you through the first forward-looking statement, which is our standard form disclaimer. I'll not bore you with the minutiae [set out in this], but if you just all please take time to read through that, that would be helpful.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)